Carfilzomib (60 mg)

admin — Wed, 18 Feb 2026 10:55:12 +0000

Overview: Bortenat 2 mg Injection contains Bortezomib (2 mg) and is a prescription targeted anticancer medicine used in the treatment of multiple myeloma and mantle cell lymphoma by inhibiting proteasome activity, leading to cancer cell death. Key Benefits: – Inhibits proteasome to trigger apoptosis in malignant cells – Effective in multiple myeloma and mantle cell lymphoma regimens – Administered under clinical supervision Composition: Bortezomib (2 mg) How It Works: Bortezomib is a proteasome inhibitor that disrupts the degradation of intracellular proteins, leading to accumulation of toxic proteins and induction of apoptosis in cancer cells, particularly in plasma cell malignancies. Usage Instructions: – Administer only under supervision of qualified healthcare professionals – Dosage and schedule determined by treatment protocol – Not for self-administration Side Effects: – Peripheral neuropathy, fatigue – Nausea, vomiting, thrombocytopenia – Injection site reactions Precautions: – Monitor blood counts and neurologic function regularly during treatment – Not recommended during pregnancy or breastfeeding unless advised by a physician – Inform your doctor of all current medications Storage Instructions: – Store refrigerated between 2-8°C, protect from light, do not freeze Manufacturer: Generic Pharmaceuticals Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.

mantle cell lymphoma medicine – Globalstar International

Carfilzomib (60 mg)